psilocybin / Revive Therap - LARVOL DELTA

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: May 2025 ➔ Aug 2025 | Trial primary completion date: May 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: University of Wisconsin, Madison | Recruiting ➔ Active, not recruiting

Enrollment closed • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: Aug 2024 ➔ May 2025 | Trial primary completion date: May 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: May 2023 ➔ May 2024

Trial completion date • Trial primary completion date • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Wisconsin, Madison | Not yet recruiting ➔ Recruiting

Enrollment open • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Wisconsin, Madison | Initiation date: Apr 2022 ➔ Jul 2022

Trial initiation date • Psychiatry

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Wisconsin, Madison

New P1 trial • Psychiatry

Revive Therapeutics Acquires Unique Psilocybin Assets (GlobeNewswire) - "The Acquired Assets will include...All intellectual and work property derived from pre-clinical research activities from the National Health Research Institutes ('NHRI') in traumatic brain injury and stroke, as it relates to psilocybin with the aim to obtain FDA Orphan Drug Designation. Key provisional patent applications with the U.S. Patent and Trademark Office, which include: Psilocybin in the Treatment of Neurological Brain Injury - United States Provisional Application Serial No. 63/011,493 – Relates to pharmaceutical compositions comprising psilocybin and their use for the treatment of neurological brain injuries and migraines; Use of Psilocybin in the Treatment of Cancer, United States Provisional Application Serial No. 63/113,913 – Psilocybin’s use of significant unmet medical needs for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia."

Patent • Preclinical • Acute Myelogenous Leukemia • Breast Cancer • CNS Disorders • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Melanoma • Migraine • Oncology

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer (GlobeNewswire) - "PharmaTher Inc...announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, the Company’s proprietary psychedelic drug repurposing artificial intelligence platform....The Company cautions that psilocybin is still under early-stage research and development and is not making any express or implied claims as to their success in cancer treatment or commercial viability."

Patent • Oncology

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics (GlobeNewswire) - "Revive Therapeutics Ltd...is pleased to announce it has entered into an exclusive research collaboration agreement with PharmaTher Inc...to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds....The collaboration will give Revive the exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI™ psychedelic discovery AI platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology."

Licensing / partnership • Oncology

Synthesis Raises US$2.75M to Develop End-to-End Professional Platform for Psychedelic Wellness & Therapy (Webwire) - "Synthesis Institute BV...has closed a US$2.75 million round of funding led by Novamind Ventures....Numerous studies have shown psilocybin experiences can greatly reduce depression and anxiety, while improving overall well-being, prompting the FDA to designate psilocybin a 'breakthrough therapy'....With their first round of funding, Synthesis seeks to scale its capacity and accessibility, evolve treatment protocols, and develop a platform that services the entire psychedelic ecosystem, including thousands of clinicians and mental health providers..."

Financing • CNS Disorders • Depression • General Anxiety Disorder